アラバマ州における鎌状赤血球症の臨床試験
アラバマ州内の拠点で、鎌状赤血球症に関する16件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- University Of Alabama, Birmingham
被験者募集中第3相
12歳〜100歳 · 全性別 · 2026/09/28更新 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- University of Alabama at Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07187973A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Uni of Alabama at Birmingham, Birmingham
- Univer South Alabama Ped/Onc, Mobile
被験者募集中第3相
12歳以上 · 全性別 · 2026/09/17更新 · NCT06612268A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- University of Alabama Birmingham, Birmingham
被験者募集中第1/2相健康なボランティア歓迎
12歳〜55歳 · 全性別 · 2026/09/09更新 · NCT06546670SCD Stem Cell Mobilization and Apheresis Using Motixafortide
- University of Alabama at Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06442761A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- University of Alabama at Birmingham, Birmingham
被験者募集中第1/2相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/08/18更新 · NCT06481306A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- AMR Clinical, Mobile
被験者募集中第2/3相
12歳以上 · 全性別 · 2026/08/18更新 · NCT05431088The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- University of Alabama at Birmingham- Site Number : 8400003, Birmingham
被験者募集中第3相
10歳〜65歳 · 全性別 · 2026/07/29更新 · NCT06975865Early Life Exposures Among Children With Sickle Cell Disease
- University of Alabama at Birmingham, Birmingham
被験者募集中
18歳〜50歳 · 女性 · 2026/07/15更新 · NCT05377372Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- University Of Alabama, Birmingham
被験者募集中第4相
6 Months – 100 Years · 全性別 · 2026/06/08更新 · NCT04657822Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Children's of Alabama (MRD-HCT), Birmingham
- Children's of Alabama (NT-DMT), Birmingham
被験者募集中観察研究
3歳〜20歳 · 全性別 · 2026/06/04更新 · NCT06941389Cognitive Remediation Intervention to Prepare for Transition of Care
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
10歳〜18歳 · 全性別 · 2026/02/27更新 · NCT05336201A Long-term Follow-up Study in Patients Who Received BEAM-101
- University of Alabama at Birmingham, Birmingham
被験者募集中観察研究
14歳〜37歳 · 全性別 · 2026/01/28更新 · NCT07373639Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- University of South Alabama Medical Center, Mobile
被験者募集中
16歳〜30歳 · 全性別 · 2026/01/07更新 · NCT06374238HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
被験者募集中観察研究
12歳〜80歳 · 全性別 · 2025/08/28更新 · NCT07145411Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
- University of Alabama, Birmingham (UAB), Birmingham
被験者募集中観察研究
18歳以上 · 全性別 · 2025/06/22更新 · NCT06385886ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。